Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct 29:8:129.
doi: 10.1186/1477-7827-8-129.

First trimester screening for trisomy 21 in gestational week 8-10 by ADAM12-S as a maternal serum marker

Niels Tørring  1 , Susan Ball, Dave Wright, Gaïané Sarkissian, Marie Guitton, Bruno Darbouret
Affiliations

First trimester screening for trisomy 21 in gestational week 8-10 by ADAM12-S as a maternal serum marker

Niels Tørring et al. Reprod Biol Endocrinol. .

Abstract

Background: A disintegrin and metalloprotease 12 (ADAM12-S) has previously been reported to be significantly reduced in maternal serum from women with fetal aneuploidy early in the first trimester and to significantly improve the quality of risk assessment for fetal trisomy 21 in prenatal screening. The aim of this study was to determine whether ADAM12-S is a useful serum marker for fetal trisomy 21 using the mixture model.

Method: In this case control study ADAM12-S was measured by KRYPTOR ADAM12-S immunoassay in maternal serum from gestational weeks 8 to 11 in 46 samples of fetal trisomy 21 and in 645 controls. Comparison of sensitivity and specificity of first trimester screening for fetal trisomy 21 with or without ADAM12-S included in the risk assessment using the mixture model.

Results: The concentration of ADAM12-S increased from week 8 to 11 and was negatively correlated with maternal weight. Log MoM ADAM12-S was positively correlated with log MoM PAPP-A (r = 0.39, P < 0.001), and with log MoM free beta hCG (r = 0.21, P < 0.001). The median ADAM12-S MoM in cases of fetal trisomy 21 in gestational week 8 was 0.66 increasing to approx. 0.9 MoM in week 9 and 10. The use of ADAM12-S along with biochemical markers from the combined test (PAPP-A, free beta hCG) with or without nuchal translucency measurement did not affect the detection rate or false positive rate of fetal aneuploidy as compared to routine screening using PAPP-A and free β-hCG with or without nuchal translucency.

Conclusion: The data show moderately decreased levels of ADAM12-S in cases of fetal aneuploidy in gestational weeks 8-11. However, including ADAM12-S in the routine risk does not improve the performance of first trimester screening for fetal trisomy 21.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ADAM12 concentration in serum is dependent on Maternal Weight. Log ADAM12-S concentration (μg/l) in maternal serum from 645 controls by gestation (top panel) and by weight (bottom panel). The superimposed lines correspond to the fitted relationship from the multiple regression model log ADAM12-S = 2.9530 + 0.01454 (gestational age (days) - 77) - 0.002421 (maternal weight - 69). The median maternal weight (67 kg) and median gestational age (66 days) have been used to obtain the fitted lines on the top and bottom panels respectively.
Figure 2
Figure 2
Biochemical markers in unaffected pregnancies. Diagnostic plots for ADAM12-S, PAPP-A and free β hCG MoM values in unaffected pregnancies.
See this image and copyright information in PMC

References

    1. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol. 2008;40:1685–1702. doi: 10.1016/j.biocel.2008.01.025. - DOI - PubMed
    1. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 1998;273:157–166. doi: 10.1074/jbc.273.1.157. - DOI - PubMed
    1. Ito N, Nomura S, Iwase A, Ito T, Kikkawa F, Tsujimoto M, Ishiura S, Mizutani S. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun. 2004;314:1008–1013. doi: 10.1016/j.bbrc.2003.12.183. - DOI - PubMed
    1. Laigaard J, Sørensen T, Frohlich C, Pedersen BN, Christiansen M, Schiøtt K, Uldbjerg N, Albrechtsen R, Clausen HV. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn. 2003;23:1086–1091. doi: 10.1002/pd.762. - DOI - PubMed
    1. Spencer K, Cowans NJ, Uldbjerg N, Tørring N. First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled? Prenat Diagn. 2008;28:338–342. doi: 10.1002/pd.1978. - DOI - PubMed

Publication types

MeSH terms